Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan-hziy in Advanced Thymoma and Thymic Carcinoma
NCT06248515Phase 2Recruiting
- Sponsor
- Georgetown University
- Start
- Apr 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in thymoma, thymic carcinoma (TC), sponsored by Georgetown University. Started Apr 2024; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on NCT06248515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06248515.